Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

121.42
Delayed Data
As of 4:00pm ET
 +3.78 / +3.21%
Today’s Change
71.63
Today|||52-Week Range
131.84
+11.99%
Year-to-Date
3 Biotech Stocks to Buy on Sale Right Now
3:48pm / MotleyFool.com - Paid Partner Content
7 Profitable Medical Stocks Ranked as Buys Now
Jun 21 / Zacks.com - Paid Partner Content
3 Healthcare Stocks That Are Looking Cheap
Jun 24 / MotleyFool.com - Paid Partner Content
7 Biotech Stocks that are Buys Right Now
Jun 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close117.64
Today’s open118.87
Day’s range117.71 - 121.98
Volume597,068
Average volume (3 months)379,808
Market cap$2.4B
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)+2,064.46%
Earnings growth (this year)+1.78%
Earnings growth (next 5 years)+53.87%
Revenue growth (last year)+11.43%
P/E ratio10.0
Price/Sales32.00
Price/Book7.71

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co-0.89-2.57%
HZNPHorizon Pharma PLC+1.08+6.89%
IPXLImpax Laboratories I...+0.29+1.01%
CBPOChina Biologic Produ...+1.68+1.61%
Data as of 4:00pm ET, 06/29/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)$0.39
Annual revenue (last year)$71.9M
Annual profit (last year)$257.3M
Net profit margin357.80%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John L. Higgins
President &
Chief Operating Officer
Matthew W. Foehr
Corporate headquarters
La Jolla, California

Forecasts

Partner Offers

Search for Jobs